Risk of drug-drug interactions in China's fight against COVID-19 and beyond

Abstract

Drug-drug interactions (DDIs) have significant impacts on patient health. In COVID-19, it is particularly important to be aware of DDIs due to the rapid development of new treatments and vaccines, as well as the widespread use of over-the-countered (OTC) drugs. Additionally, people who have COVID-19 may also be taking medications for comorbid conditions, increasing the potential for DDIs. Beyond the COVID-19 pandemic, the issue of drug interactions is further exacerbated by the aging population...

Publication DOI: https://doi.org/10.1016/j.phrs.2023.106903
Divisions: College of Health & Life Sciences > Aston Pharmacy School
Aston University (General)
Funding Information: This work was supported by the Research Grants Council of the Hong Kong Special Administrative Region, China (Grant Nos. 11218221, C7154-20GF, C7151-20GF and C1143-20GF).
Additional Information: Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/).
Uncontrolled Keywords: COVID-19,Drug interactions,Network science,Protein-protein interactions,Pharmacology
Publication ISSN: 1096-1186
Last Modified: 15 Jul 2025 07:14
Date Deposited: 14 Jul 2025 11:35
Full Text Link:
Related URLs: http://www.scop ... tnerID=8YFLogxK (Scopus URL)
https://www.sci ... 2591?via%3Dihub (Publisher URL)
PURE Output Type: Letter
Published Date: 2023-10
Published Online Date: 2023-09-09
Accepted Date: 2023-08-31
Authors: Zhang, Qingpeng
Yang, Jiannan
Zeng, Daniel Dajun
Feng, Yibin
Wong, Ian C.K. (ORCID Profile 0000-0001-8242-0014)

Download

[img]

Version: Published Version

License: Creative Commons Attribution


Export / Share Citation


Statistics

Additional statistics for this record